These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1036842)

  • 1. Platelet aggregation following defibrination with ancrod.
    Slade CL; Andes WA; Mason AD
    Thromb Haemost; 1976 Nov; 36(2):424-9. PubMed ID: 1036842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiplatelet activity of ancrod on administration to rabbits.
    Chang MC; Huang TF
    J Lab Clin Med; 1995 Apr; 125(4):508-16. PubMed ID: 7706907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in blood flow through a critical arterial stenosis by defibrination with ancrod.
    Barrie WW; Schenk WG
    Arch Surg; 1976 May; 111(5):561-3. PubMed ID: 1267605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
    Simpson PJ; Schelm JA; Smith GF
    J Pharmacol Exp Ther; 1991 Feb; 256(2):780-6. PubMed ID: 1704437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.
    Daniel TM; Pizzo SV; Mckee PA
    Ann Surg; 1976 Aug; 184(2):223-8. PubMed ID: 952568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
    Bell WR; Shapiro SS; Martinez J; Nossel HL
    J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alterations of plasma plasminogen and fibrinogen, serum fibrin degradation products and degree of ADP induced platelet aggregation in acute myocardial infarction (author's transl)].
    Zhonghua Xin Xue Guan Bing Za Zhi; 1979; 7(1):49-52. PubMed ID: 550980
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of defibrination on tumor growth and response to chemotherapy.
    DeWys WD; Kwaan HC; Bathina S
    Cancer Res; 1976 Oct; 36(10):3584-7. PubMed ID: 953985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
    Pollak VE; Glueck HI; Weiss MA; Lebron-Berges A; Miller MA
    Am J Nephrol; 1982; 2(4):195-207. PubMed ID: 6816068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension.
    Miller KW; Keith JC
    Thromb Haemost; 1988 Dec; 60(3):365-71. PubMed ID: 3238644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG; Nelson SR; Hampton KK; Casali B; Boothby M; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of blood clotting factors in anaphylactic and primary and secondary endotoxin shock.
    Ferrell WJ; Jabs CM; Robb HJ; Mammen EF
    Ann Clin Lab Sci; 1983; 13(4):291-8. PubMed ID: 6194736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation by ancrod for carbon dioxide removal by extracorporeal membrane lung in the dog.
    Sinclair ME; Reber G; Schweizer A; Dorrington KL; De Moerloose P; Bouvier CA; Gardaz JP
    J Thorac Cardiovasc Surg; 1989 Feb; 97(2):275-81. PubMed ID: 2492625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
    Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between products of fibrin degradation and platelet dysfunction in chronic renal failure. Effects of aspirin].
    Lazzari MA; Pavlovsky M; Martínez Canaveri A
    Medicina (B Aires); 1977; 37(2):97-105. PubMed ID: 895494
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory effect of staphylokinase on platelet aggregation.
    Suehiro A; Oura Y; Ueda M; Kakishita E
    Thromb Haemost; 1993 Nov; 70(5):834-7. PubMed ID: 7510426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble fibrin complex production and proteolysis during ancrod therapy.
    McKillop C; Edgar W; Prentice CR; Forbes CD
    Scott Med J; 1975 May; 20(3):139-40. PubMed ID: 127379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.